Aligos Therapeutics Inc.

15.83+0.1800+1.15%Vol 40.32K1Y Perf 6.60%
Sep 23rd, 2021 14:14 DELAYED
BID15.70 ASK15.81
Open15.81 Previous Close15.65
Pre-Market- After-Market-
 - -%  - -
Target Price
33.80 
Analyst Rating
— — 0.00
Potential %
114.60 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     48.94
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
12.19 
Earnings Rating
Market Cap674.50M 
Earnings Date
4th Nov 2021
Alpha-0.05 Standard Deviation0.24
Beta2.55 

Today's Price Range

15.3215.92

52W Range

12.8237.51

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-4.46%
1 Month
-3.28%
3 Months
-37.57%
6 Months
-26.46%
1 Year
6.60%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALGS15.830.18001.15
AAPL146.800.95000.65
GOOG2 840.4721.70000.77
MSFT299.751.17000.39
XOM57.101.89003.42
WFC48.060.98002.08
JNJ165.381.45000.88
FB346.082.87000.84
GE103.595.05005.12
JPM161.655.74003.68
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.81-0.792.47
Q01 2021-0.90-0.7417.78
Q04 2020-0.90-1.09-21.11
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.83
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume40.32K
Shares Outstanding42.61M
Shares Float19.12M
Trades Count772
Dollar Volume2.18M
Avg. Volume161.90K
Avg. Weekly Volume333.14K
Avg. Monthly Volume304.38K
Avg. Quarterly Volume313.16K

Aligos Therapeutics Inc. (NASDAQ: ALGS) stock closed at 15.65 per share at the end of the most recent trading day (a 0.97% change compared to the prior day closing price) with a volume of 137.07K shares and market capitalization of 674.50M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 73 people. Aligos Therapeutics Inc. CEO is Lawrence M. Blatt.

The one-year performance of Aligos Therapeutics Inc. stock is 6.6%, while year-to-date (YTD) performance is -43.4%. ALGS stock has a five-year performance of %. Its 52-week range is between 12.82 and 37.51, which gives ALGS stock a 52-week price range ratio of 12.19%

Aligos Therapeutics Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 4.09, a price-to-sale (PS) ratio of 246.27, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -67.91%, a ROC of -78.98% and a ROE of -84.15%. The company’s profit margin is -%, its EBITDA margin is -4 463.50%, and its revenue ttm is $2.46 Million , which makes it $0.06 revenue per share.

Of the last four earnings reports from Aligos Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.83 for the next earnings report. Aligos Therapeutics Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Aligos Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Aligos Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aligos Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aligos Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.03, ATR14 : 0.99, CCI20 : -82.38, Chaikin Money Flow : -0.16, MACD : -0.17, Money Flow Index : 36.83, ROC : -8.26, RSI : 46.15, STOCH (14,3) : 37.70, STOCH RSI : 0.38, UO : 42.80, Williams %R : -62.30), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aligos Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Aligos Therapeutics Inc.

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).

CEO: Lawrence M. Blatt

Telephone: +1 800 466-6059

Address: One Corporate Drive, South San Francisco 94080, CA, US

Number of employees: 73

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

83%17%

Bearish Bullish

75%25%

News

Stocktwits